DESTINY-BREAST03 Flashcards
1
Q
What?
A
Enhurtu vs Kadcyla
(Deruxtecan) vs (Emtansine)
2
Q
Who?
A
Metastatic HER2 breast cancer progressed on taxable and anti-HER2
3
Q
How?
A
524 randomly assigned patients
4
Q
What was the 12 month progression free survivals?
A
75.8% vs 34.1%
5
Q
What was the 12 month progression free survivals?
A
75.8% vs 34.1%
6
Q
What percentage of people were alive at 12 months?
A
94.1% vs 85.9%
7
Q
What was the overall response rate?
A
79.7% vs. 34.2%
8
Q
What was the percentage of any Grade adverse events?
A
98.1% va 86.6%
9
Q
What percentage had adverse events G3-G4?
A
45.1% vs 39.8%
